NANobuya Abe

Nobuya Abe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nobuya Abe has a total of 123 co-authors. Here are the top co-authors by number of shared publications:

  • Tatsuya Atsumi

    Hokkaido University Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Sapporo 0608648 , Japan

    15 shared publications
  • Michihito Kono

    Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University

    10 shared publications
  • Yuichiro Fujieda

    Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan

    10 shared publications
  • Hideki Kasahara

    Department of Rheumatology, NTT Sapporo Medical Center, Sapporo, Japan

    8 shared publications
  • Kohei Karino

    Hokkaido University Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Sapporo 0608648 , Japan

    7 shared publications
  • Miyuki Bohgaki

    Department of Rheumatology, NTT Sapporo Medical Center, Sapporo, Japan

    7 shared publications

Latest Publications

  • Sulfasalazine as a Prophylactic for Pneumocystis Pneumonia in Patients With Rheumatoid Arthritis: A Cohort Study

    by Masaru Yoshimura, Nobuya Abe, Michihito Kono, Koji Oba, Yuichiro Fujieda, Masaru Kato, Olga Amengual, Tatsuya Atsumi

    Aim: We investigated the potential of sulfasalazine (SSZ), one of the conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs), as primary prophylaxis for pneumocystis pneumonia (PCP) in patients with rheumatoid arthritis (RA). Methods: In this longitudinal cohort study, we enrolled patients with RA who started receiving new RA treatment. A treatment episode was defined as a period of 1 year from the start or increase of DMARDs dose, or starting prednisolone > 10 mg/day, and the incidence of PCP in this period was assessed. All treatment episodes were classified into two groups based on the presence of SSZ at baseline. The PCP incidence rate in the two groups was evaluated using a negative binomial regression model. Results: A total of 848 treatment episodes were recorded in 594 RA patients: 181 and 667 in the SSZ and control groups, respectively. During the 850.6 person‐years of observation, 21 patients developed PCP, and three died of PCP. Multivariable adjusted analysis using Firth's method showed that the 1‐year incidence of PCP was significantly reduced with SSZ treatment ( p = 0.003, rate ratio = 0.05; 95% CI 0.00–0.34). Furthermore, the log‐rank test in the propensity score‐matched population confirmed this result. Regarding safety, 45 adverse drug reactions related to SSZ occurred (4.34/100 person‐years; 95% CI 3.26–5.78). Only one serious adverse reaction (drug‐induced hypersensitivity syndrome) was observed, which resolved after discontinuation of SSZ. Conclusion: We demonstrated the preventive efficacy of SSZ on PCP. The pleiotropic effect of this traditional DMARD may impact RA treatment, providing another option for PCP prophylaxis.


  • GM-CSF Promotes the Survival of Peripheral-Derived Myeloid Cells in the Central Nervous System for Pain-Induced Relapse of Neuroinflammation

    by Shiina Matsuyama, Reiji Yamamoto, Kaoru Murakami, Nobuhiko Takahashi, Rieko Nishi, Asuka Ishii, Junko Nio-Kobayashi, Nobuya Abe, Kumiko Tanaka, Jing-Jing Jiang, et al.

    We recently discovered a (to our knowledge) new neuroimmune interaction named the gateway reflex, in which the activation of specific neural circuits establishes immune cell gateways at specific vessel sites in organs, leading to the development of tissue-specific autoimmune diseases, including a multiple sclerosis (MS) mouse model, experimental autoimmune encephalomyelitis (EAE). We have reported that peripheral-derived myeloid cells, which are CD11b+MHC class II+ and accumulate in the fifth lumbar (L5) cord during the onset of a transfer model of EAE (tEAE), play a role in the pain-mediated relapse via the pain-gateway reflex. In this study, we investigated how these cells survive during the remission phase to cause the relapse. We show that peripheral-derived myeloid cells accumulated in the L5 cord after tEAE induction and survive more than other immune cells. These myeloid cells, which highly expressed GM-CSFRα with common β chain molecules, grew in number and expressed more Bcl-xL after GM-CSF treatment but decreased in number by blockade of the GM-CSF pathway, which suppressed pain-mediated relapse of neuroinflammation. Therefore, GM-CSF is a survival factor for these cells. Moreover, these cells were colocalized with blood endothelial cells (BECs) around the L5 cord, and BECs expressed a high level of GM-CSF. Thus, GM-CSF from BECs may have an important role in the pain-mediated tEAE relapse caused by peripheral-derived myeloid cells in the CNS. Finally, we found that blockade of the GM-CSF pathway after pain induction suppressed EAE development. Therefore, GM-CSF suppression is a possible therapeutic approach in inflammatory CNS diseases with relapse, such as MS.


  • Dynamics of corticocortical brain functional connectivity relevant to therapeutic response to biologics in inflammatory arthritis

    by Kodai Sakiyama, Nobuya Abe, Yuichiro Fujieda, Khin K Tha, Hisashi Narita, Kohei Karino, Masatoshi Kanda, Michihito Kono, Masaru Kato, Tatsuya Atsumi

    Aberrant functional connectivity (FC) of the brain regions, evaluated by functional magnetic resonance imaging (fMRI), affects clinical courses in inflammatory arthritis (IA). The static analysis methods would be simplistic to estimate the whole picture of resting-state brain function because blood oxygen level-dependent (BOLD) signals fluctuate over time. The effects of FC dynamics on clinical course are unknown in IA. Therefore, we aimed to evaluate dynamic FC for therapeutic responsiveness to biologics in IA patients. We analyzed resting-state fMRI data of 64 IA patients in 2 cohorts. Dynamic FC was derived as a correlation coefficient of the windowed BOLD signal time series. We determined representative whole-brain dynamic FC patterns by k-means++ cluster analysis, leading to 4 distinct clusters. In the first cohort, occurrence probability of the distinct cluster was associated with favorable therapeutic response in disease activity and patients’ global assessment, which was validated by the second cohort. The whole-brain FC of the distinct cluster indicated significantly increased corticocortical connectivity, and probabilistically decreased after therapy in treatment-effective patients compared with -ineffective patients. Taken together, frequent emergence of corticocortical connections was associated with clinical outcomes in IA. The coherence of corticocortical interactions might affect pain modulation, possibly relevant to therapeutic satisfaction.


  • Inhibitor of NF‐κB Kinase Subunit ε Contributes to Neuropsychiatric Manifestations in Lupus‐Prone Mice Through Microglial Activation

    by Kohei Karino, Michihito Kono, Shuhei Takeyama, Yuki Kudo, Masatoshi Kanda, Nobuya Abe, Kuniyuki Aso, Yuichiro Fujieda, Masaru Kato, Kenji Oku, et al.

    Objective: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by multiorgan dysfunction. Neuropsychiatric SLE (NPSLE) occurs in 30–40% of lupus patients and is the most severe presentation of SLE, frequently resulting in limitation of daily life. Recent studies have shown that microglia, tissue‐resident macrophages in the central nervous system, are involved in the pathogenesis of NPSLE. This study was undertaken to explore new therapeutic targets for NPSLE focusing on microglia.Methods: RNA sequencing of microglia in MRL/lpr, lupus‐prone mice, as well as that of microglia cultured in vitro with cytokines were performed. A candidate gene, which could be a therapeutic target for NPSLE, was identified, and its role in microglial activation and phagocytosis was investigated using specific inhibitors and small interfering RNA. The effect of intracerebroventricular administration of the inhibitor on the behavioral abnormalities of MRL/lpr was also evaluated.Results: Transcriptome analysis revealed the up‐regulation of Ikbke, which encodes the inhibitor of NF‐κB kinase subunit ɛ (IKBKε) in both microglia from MRL/lpr mice and cytokine‐stimulated microglia in vitro. Intracerebroventricular administration of an IKBKε inhibitor ameliorated cognitive function and suppressed microglial activation in MRL/lpr mice. Mechanistically, IKBKε inhibition reduced glycolysis, which dampened microglial activation and phagocytosis.Conclusion: These findings suggest that IKBKε plays a vital role in the pathogenesis of NPSLE via microglial activation, and it could serve as a therapeutic target for NPSLE.


  • Dramatic improvement with colchicine in antihistamine- and omalizumab-resistant chronic spontaneous urticaria

    by Nobuya Abe, Miyuki Bohgaki, Hideki Kasahara

    Chronic spontaneous urticaria (CSU) is defined as the presence of recurrent urticaria, angioedema or both without any specific triggers, which persists for ≥ 6 weeks. Refractory cases to standard therapeutic regimens including antihistamines, immunosuppressants and biologics have been reported. Therefore, it is crucial to evolve novel therapeutic strategies through accumulating refractory CSU cases, which are successfully treated. We here report a refractory case of CSU to antihistamines and omalizumab, which was dramatically improved with colchicine.


  • Regulation of NETosis and Inflammation by Cyclophilin D in Myeloperoxidase‐Positive Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

    by Takashi Kudo, Daigo Nakazawa, Kanako Watanabe‐Kusunoki, Masatoshi Kanda, Satoka Shiratori‐Aso, Nobuya Abe, Saori Nishio, Jun‐Ichiro Koga, Sari Iwasaki, Takahiro Tsuji, et al.

    Objective: Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) is pathologically characterized by focal fibrinoid necrosis, in which ANCA‐mediated neutrophil extracellular trap (NET) formation and subsequent endothelial cell necrosis occur. Cyclophilin D (CypD) plays an important role in mediation of cell necrosis and inflammation via the opening of mitochondrial permeability transition pores. This study was undertaken to examine the role of CypD in AAV pathogenesis.Methods: We assessed the role and mechanism of CypD in ANCA‐stimulated neutrophils in vitro by immunostaining and electron microscopy observation. We performed a comprehensive RNA‐sequencing analysis on ANCA‐treated murine neutrophils. To investigate the role of CypD in vivo, we assessed disease features in CypD‐knockout mice and wild‐type mice using 2 different murine AAV models: anti‐myeloperoxidase IgG transfer–induced AAV and spontaneous AAV.Results: In vitro experiments showed that pharmacologic and genetic inhibition of CypD suppressed ANCA‐induced NET formation via the suppression of reactive oxygen species and cytochrome c release from the mitochondria. RNA‐sequencing analyses in ANCA‐treated murine neutrophils revealed the involvement of inflammatory responses, with CypD deficiency reducing ANCA‐induced alterations in gene expression. Furthermore, analyses of upstream regulators revealed the relevance of intracellular calcium (CypD activator) and cyclosporin (CypD inhibitor) in ANCA stimulation, indicating that the CypD‐dependent opening of mitochondrial permeability transition pores is associated with ANCA‐induced neutrophil activation and NETosis. In both AAV mouse models, the genetic deletion of CypD ameliorated crescentic glomerulonephritis via the inhibition of CypD‐dependent neutrophil and endothelial necrosis.Conclusion: CypD targeting is a novel and specific therapeutic strategy for AAV via the resolution of necrotizing vasculitis.